SoftBank Vision Fund 2 helped microbial therapeutics developer Hexagon tip its overall funding to over $108m.

US-based biopharmaceutical company Hexagon Bio carried out a $61m funding round featuring telecommunications and internet group SoftBank’s Vision Fund 2 on Wednesday, bringing its total funding to over $108m.

The round was led by Nextech Invest and included Casdin Capital, 8VC, The Column Group and Two Sigma Ventures.

Founded in 2016, Hexagon is developing therapies for diseases using compounds from microbial genomes, primarily from fungi, using an interdisciplinary platform that incorporates genomics, data science and synthetic biology.

Proceeds from the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn